Coleman RL - Search Results

1

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.

Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. Coleman RL, et al. Gynecol Oncol. 2015 Jun;137(3):386-91. doi: 10.1016/j.ygyno.2015.03.042. Epub 2015 Mar 24. Gynecol Oncol. 2015. PMID: 25818403 Free PMC article. Clinical Trial.

2

Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy.

Burke TW, Levenback C, Coleman RL, Morris M, Silva EG, Gershenson DM. Burke TW, et al. Among authors: coleman rl. Gynecol Oncol. 1995 May;57(2):215-20. doi: 10.1006/gyno.1995.1128. Gynecol Oncol. 1995. PMID: 7729737 Clinical Trial.

3

Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy.

Coleman RL, Keeney ED, Freedman RS, Burke TW, Eifel PJ, Rutledge FN. Coleman RL, et al. Gynecol Oncol. 1994 Oct;55(1):29-35. doi: 10.1006/gyno.1994.1242. Gynecol Oncol. 1994. PMID: 7959262

4

In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer.

von Gruenigen VE, Santoso JT, Coleman RL, Muller CY, Miller DS, Mathis JM. von Gruenigen VE, et al. Among authors: coleman rl. Gynecol Oncol. 1998 Jun;69(3):197-204. doi: 10.1006/gyno.1998.5010. Gynecol Oncol. 1998. PMID: 9648587

5

Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer.

Levenback C, Coleman RL, Burke TW, Bodurka-Bevers D, Wolf JK, Gershenson DM. Levenback C, et al. Among authors: coleman rl. Gynecol Oncol. 2001 Nov;83(2):276-81. doi: 10.1006/gyno.2001.6374. Gynecol Oncol. 2001. PMID: 11606084 Clinical Trial.

6

Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.

Schorge JO, Mahoney NM, Miller DS, Coleman RL, Muller CY, Euhus DM, Tomlinson GE. Schorge JO, et al. Among authors: coleman rl. Gynecol Oncol. 2001 Nov;83(2):383-7. doi: 10.1006/gyno.2001.6431. Gynecol Oncol. 2001. PMID: 11606101

7

Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies.

Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL. Drake RD, et al. Among authors: coleman rl. Gynecol Oncol. 2004 Aug;94(2):320-4. doi: 10.1016/j.ygyno.2004.05.027. Gynecol Oncol. 2004. PMID: 15297168 Clinical Trial.

8

Critical evaluation of secondary cytoreduction in recurrent ovarian cancer.

Munkarah AR, Coleman RL. Munkarah AR, et al. Among authors: coleman rl. Gynecol Oncol. 2004 Nov;95(2):273-80. doi: 10.1016/j.ygyno.2004.09.018. Gynecol Oncol. 2004. PMID: 15491746 Review.

9

Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer.

Bhoola SM, Coleman RL, Herzog T, Morris R, Bryant C, Estes JM, Alvarez RD. Bhoola SM, et al. Among authors: coleman rl. Gynecol Oncol. 2004 Dec;95(3):564-9. doi: 10.1016/j.ygyno.2004.08.026. Gynecol Oncol. 2004. PMID: 15581964

10

Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.

Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL. Rao GG, et al. Among authors: coleman rl. Gynecol Oncol. 2005 Jan;96(1):168-72. doi: 10.1016/j.ygyno.2004.09.009. Gynecol Oncol. 2005. PMID: 15589596 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

589 results

Search Page